Q4 2024 Earnings Call Transcript February 10, 2025 Inspire Medical Systems, Inc. beats earnings expectations. Reported EPS is ...

Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 24.5% year on year to $239.7 million.

Inspire Medical Systems (NYSE:INSP – Free Report) had its price target trimmed by Morgan Stanley from $230.00 to $220.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm ...

Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 24.5% year on year to $239.7 million. The company ...

Medical technology company Inspire Medical Systems (NYSE:INSP) will be reporting results tomorrow after market close. Here’s what you need to know. Inspire Medical Systems beat analysts ...

Check Out Our Latest Stock Analysis on INSP Inspire Medical Systems Stock Down 5.7 % Shares of NYSE INSP opened at $181.14 on Friday. Inspire Medical Systems, Inc. has a 52-week low of $123.00 and ...

Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q4 CY2024 results , with sales up 24.5% year on year ...

MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative ...

MORGANTOWN, W. Va.--(BUSINESS WIRE)--Infinity Natural Resources, Inc. (“Infinity”) (NYSE: INR) announced today that Infinity President and CEO Zack Arnold and EVP and CFO David Sproule will be joined ...

Inspire Medical Systems (NYSE:INSP) reported Q2 EPS of ($0.53), $0.08 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $91.4 million versus the... Leerink Partners ...

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with ...

Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating ...